Carlsmed, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CARL research report →
Range $17 – $26
Price Chart
About the company
Carlsmed, Inc. , a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
- CEO
- Michael Cordonnier
- IPO
- 2025
- Employees
- 127
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on CARL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $477.38M
- P/E
- -12.53
- PEG
- -0.35
- P/S
- 6.75
- P/B
- 6.38
- EV/EBITDA
- -16.89
- Div Yield
- 0.00%
- Gross Margin
- 76.96%
- Op Margin
- -58.98%
- Net Margin
- -55.82%
- ROE
- -45.65%
- ROIC
- -43.27%
Latest fiscal year · YoY change
- Revenue
- $50.51M+85.9%
- Gross Profit
- $38.04M+89.7%
- Op Income
- $-30,574,000
- Net Income
- $-29,634,000-22.2%
- EPS
- $-2.12-41.3%
- OCF Growth
- -13.8%
- FCF Growth
- -15.5%
- 52W High
- $19.15
- 52W Low
- $8.50
- 50D MA
- $15.15
- 200D MA
- $12.65
- Beta
- 1.97
- RSI (14)
- 59
- Avg Volume
- 112.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Carlsmed posted 65% Q3 revenue growth, expanded gross margin, and raised full-year guidance as cervical adoption, new lumbar reimbursement, and new product launches point to continued momentum into 2027.· November 10, 2026
- Q3 revenue was $21.6 million, up 65% from $13.1 million last year, driven by surgeon adds, higher utilization, and the cervical launch.
- Gross margin reached 77.3%, up about 140 basis points year over year, and adjusted EBITDA improved to negative $7.3 million from negative $8.2 million.
- Management raised full-year 2026 revenue guidance to $78 million-$80 million from $74 million-$78 million.
- Cervical made up 12% of Q3 revenue, while lumbar remained 88%; management said cervical adoption is running above initial expectations.
- The company highlighted the October 1 lumbar DRG change, the recent launch of the posterior bilateral lumbar procedure, and the upcoming cervical plating launch as 2027 catalysts.
Revenue for Q3 2026 was $21.6 million, up 65% year over year from $13.1 million in Q3 2025. Gross margin was 77.3%, compared with 75.9% a year ago, roughly a 140 basis point improvement. Adjusted EBITDA was negative $7.3 million versus negative $8.2 million in Q3 2025, and adjusted net loss per share was negative $0.34. Cash, restricted cash and investments totaled $80.3 million at September 30, 2026, with quarterly cash burn of $9 million and term loan debt of $15.6 million. Full-year 2026 revenue guidance was raised to $78 million-$80 million, with management expecting gross margin to remain in the high 70s. For Q4, the company expects stock-based compensation of $2.75 million-$3 million and weighted average shares outstanding of 27.3 million-27.6 million.
Mike Cordonnier framed the quarter as an inflection point, emphasizing strong adoption of Carlsmed’s AI-enabled personalized surgery platform and the company’s capital-light model. He said the business is gaining momentum from clinical evidence, faster surgeon onboarding, deeper utilization, and new reimbursement support, and described the lumbar DRG change and cervical launch as important catalysts heading into 2027. His tone was confident and constructive, with repeated emphasis on long-term scale and the company’s aim to become a broader standard in spine surgery.
Rich Heppenstall focused on the improving financial profile, citing $21.6 million of revenue, 77.3% gross margin, and adjusted EBITDA of negative $7.3 million. He said gross margin improved from lower per-unit contract manufacturing costs and operating efficiency in the digital production system, while cash and investments ended at $80.3 million with $9 million of quarterly cash burn. He also provided guidance details: full-year revenue of $78 million-$80 million, gross margin expected in the high 70s, and Q4 stock-based compensation of $2.75 million-$3 million.
Analysts focused on the impact of the new lumbar DRGs, cervical mix, new surgeon additions, and whether Q4 guidance was conservative despite visible momentum. Management said it saw an uptick in new hospital contracts exiting Q3 and continuing into Q4, and reiterated that the DRG change should help hospital access and support 2027 volume. On cervical, the company said it represented 12% of Q3 revenue and was ramping faster than initially expected. Management also said it remains the only pure-play personalized surgery company and described the guidance approach as prudent for a newly public high-growth med tech company.
The bull case from this call is that Carlsmed is showing strong top-line growth with improving margins and early operating leverage. Management pointed to multiple near- and medium-term catalysts: the new lumbar reimbursement structure, the launch of the posterior bilateral procedure, the impending cervical plating launch, and continued rapid surgeon adoption.
The main risks are that the company is still loss-making, with negative adjusted EBITDA and quarterly cash burn of $9 million. Growth also depends on continued hospital adoption, successful execution on new product launches, and reimbursement tailwinds translating into actual procedure volume; management acknowledged it is still early and responded to competition questions by stressing differentiation rather than quantifying market share risk.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 37.4%
- Shares Outstanding
- 27.40M
- Float Shares
- 10.25M
of shares held by institutions
77 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 1.25M | ▲ 1.25M |
| Parkman Healthcare Partners LLC | 779.76K | ▲ 182.44K |
| Janus Henderson Group Ltd. | 726.20K | ▲ 726.20K |
| Blackrock, Inc. | 581.66K | ▲ 49.07K |
| Pier Capital, LLC | 518.71K | ▲ 145.03K |
| Cadian Capital Management, LP | 500.10K | ▲ 500.10K |
| Point72 Asset Management, L.P. | 495.82K | ▲ 495.82K |
| Vanguard Group Inc | 360.08K | ▲ 132.89K |
| Vanguard Capital Management LLC | 281.41K | ▲ 42.68K |
| Palumbo Wealth Management LLC | 265.89K | ▼ 1.41K |
| Russell Investments Group, Ltd. | 257.81K | ▲ 118.66K |
| Geode Capital Management, LLC | 234.90K | ▲ 30.25K |
Held by 99 ETFs
Biggest fund positions in CARL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Bertolini Jeffrey | other | 747 |
| Nov 3, 26 | Bertolini Jeffrey | sell | 747 |
| Nov 3, 26 | Bertolini Jeffrey | other | 747 |
| Oct 30, 26 | Bertolini Jeffrey | other | 243 |
| Oct 30, 26 | Bertolini Jeffrey | sell | 243 |
| Oct 30, 26 | Bertolini Jeffrey | other | 243 |
| Oct 5, 26 | Bertolini Jeffrey | other | 747 |
| Oct 5, 26 | Bertolini Jeffrey | sell | 747 |
| Oct 5, 26 | Bertolini Jeffrey | other | 747 |
| Sep 30, 26 | Bertolini Jeffrey | other | 243 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CARL coverage
Recent articles, reports, and earnings notes.
No research on CARL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CARL report →Carlsmed to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 16
Carlsmed: The Reimbursement Reset Is Not Yet In The Numbers
seekingalpha.com · Nov 14
These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results
benzinga.com · Nov 11
Carlsmed Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Carlsmed, Inc. (CARL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Carlsmed, Inc. (CARL) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 10
Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
globenewswire.com · Nov 10
Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.